Read a state ranking as a set of claims to test, not a finding to accept. The claim that matters most, that a given service can legally treat and ship to you right now, expires without notice and is rarely dated on the page. Verify it on the provider’s own eligibility screen and against your state boards.
The claim with the shortest shelf life
“Available in 50 states” is the line that ages worst. Availability rests on two moving parts: clinicians licensed in each state, and a dispensing pharmacy cleared to ship into it. Both change as staff turn over, contracts end, and pharmacy partners are swapped. A ranking published in spring can list a service as available in a state it exited months later, and nothing on the page will tell you.
Three habits catch most of this. Look for a visible last-updated date rather than a copyright year in the footer. Check whether the article names the licensing mechanism at all, since writers who understand the subject tend to mention prescriber licensure and nonresident pharmacy licensure by name. Then take the shortlist to each provider’s own eligibility check, which reflects current status because the company has a commercial reason to keep it accurate.
Who paid for the ranking
Most state roundups earn money in one of three ways, and each bends the result differently. Affiliate publishers are paid per signup, so the ordering tends to follow commission rather than fit. Platforms publish rankings that include themselves, which is not automatically disqualifying but does mean the criteria were chosen by an interested party. A smaller group of medical and consumer publications run editorial reviews with no commercial link, and those are the ones worth reading closely even when they cover fewer services.
Disclosure language is a useful tell. A site that states its affiliate relationships plainly is usually easier to read against than one that omits any mention of how it is funded. Detailed state pages published by the platforms themselves can still carry real information. A state-by-state comparison hosted at formblends.com is one example of a page written by a company that appears on it, and the way to use material of that kind is to treat every figure as a lead to be confirmed rather than a result. The same test applies to competing pages from Ro, Hims and Hers, Noom, Found, and Henry Meds.
Sorting claim types
| Claim you will see | What it usually rests on | How to test it |
|---|---|---|
| “Available in your state” | Current prescriber and pharmacy coverage, undated | Run the provider’s eligibility check with your own address |
| “Licensed providers” | True of any lawful service, so it distinguishes nothing | Search the named clinician in your state medical board’s lookup |
| “US-based pharmacy” | Location, which is not the same as licensure where you live | Check the pharmacy against your state board of pharmacy |
| “FDA-registered facility” | Registration, which is not FDA approval of a product | Look up outsourcing facilities on FDA’s published registration list |
| “Average patient lost X percent” | Usually trial data for the molecule, restated as a program outcome | Trace it to the trial, then check the population and duration |
| “Starting at $X per month” | An entry dose, often with a prepaid commitment | Price the strength you would reach by month six, with all fees |
Applying that table to named services is the whole point of the exercise. Rankings will list Ro, Hims and Hers, Henry Meds, and HealthRX in different orders depending on who is paying for the placement, but the underlying claims about who can prescribe and ship GLP-1 medications in your state resolve the same way for every one of them: on the provider’s own eligibility screen and at your state boards, not in the headline a roundup chose.
Clinical claims copied into commercial pages
Weight-loss percentages travel a long way from their source. Semaglutide’s registration trial ran 68 weeks in a defined population with intensive lifestyle support built into the protocol. Tirzepatide’s trial was a separate study with its own population and a 72-week duration. Presenting the two headline numbers side by side as a contest is a cross-trial comparison, and any page doing so without saying as much is being loose with the evidence. A later randomized comparison of the two molecules exists and is the appropriate citation for a direct claim.
Trial results also describe the molecule, not the vendor. No compounded program has run its own registration trial, so a percentage attached to a brand name in a roundup is almost always borrowed. Clinical practice guidance on obesity pharmacotherapy is a better anchor for what these drugs do in routine care than any provider’s marketing summary.
The approval question that rankings blur
Compounded semaglutide and compounded tirzepatide are not FDA-approved products. FDA has not evaluated those preparations for safety, effectiveness, or manufacturing quality, and it has published concerns about unapproved GLP-1 drugs sold for weight loss. Compounding of copies of approved drugs is also constrained by federal law and tied to shortage status, which FDA publishes and updates. A ranking that lists compounded and brand programs in one column without flagging that difference is comparing two regulatory categories as though they were one.
Coverage claims are state claims
Statements about insurance in a national roundup deserve the least trust of all, because coverage of anti-obesity medication is decided plan by plan and, for Medicaid, state by state. Medicare drug coverage has historically excluded agents used solely for weight loss. A page asserting that a service “works with insurance” is describing a billing capability, not a promise that your plan pays. Your state Medicaid agency and your own formulary settle it.
Frequently asked questions
Are user reviews useful for picking a provider in my state?
They are useful for service questions such as shipping delays and support response, and close to useless for clinical quality or state availability. Reviewers rarely say where they live or when they enrolled, so a positive review from another state tells you nothing about whether you can even sign up.
Why do two roundups list different states for the same service?
Usually because they were written at different times. Coverage maps change as licensure and pharmacy arrangements change. It can also happen when one writer counts states where consultations are offered and another counts states where medication actually ships, which are not always the same list.
Does an accreditation seal on a review page mean anything?
It depends entirely on the issuing body. Pharmacy accreditation programs run by recognized organizations involve real inspection. Site badges that are simply images with no verifiable registry entry behind them mean nothing. If a seal does not link to a searchable record, treat it as decoration.
How current does a state page need to be?
For pricing and availability, months rather than years. A page more than a year old should be treated as a source of questions, not answers. Clinical background in an older article can still hold, since trial results do not change, but the operational claims around them almost certainly have.
Is a paid ranking always biased?
Not always, but the ordering is the part to distrust first. Paid placements often produce accurate factual detail while arranging it to favor the highest-paying option. Reading such a page for its criteria, then applying those criteria yourself, extracts the value without inheriting the ranking.
